La , une bact rie pas comme les autres

Ciprofloxacin (CIP) a broad-spectrum antibiotic, is used extensively for the treatment of diverse infections and diseases of bacteria origin, and this includes infections caused by E. coli; P. aeruginosa; S. aureus; and MRSA. This extensive use of CIP has therefore led to an increase in resistance by these infection causing organisms. Nano delivery systems has recently proven to be a possible solution to resistance to these organisms. They have been applied as a strategy to improve the target specificity of CIP against infections and diseases caused by these organisms, thereby maximising the efficacy of CIP to overcome the resistance. Herein, we proffer a brief overview of the mechanisms of resistance; the causes of resistance; and the various approaches employed to overcome this resistance. The review then proceeds to critically evaluate various nano delivery systems including inorganic based nanoparticles; lipid-based nanoparticles; capsules, dendrimers, hydrogels, micelles, and polymeric nanoparticles; and others; that have been applied for the delivery of CIP against E. coli; P. aeruginosa; S. aureus; and MRSA infections. Finally, the review highlights future areas of research, for the optimisation of various nano delivery systems, to maximise the therapeutic efficacy of CIP against these organisms. This review confirms the potential of nano delivery systems, for addressing the challenges of resistance to caused by E. coli; P. aeruginosa; S. aureus; and MRSA to CIP

Antibiotic resistance · Antibiotics · Bacteria · Biology · Ciprofloxacin · Delivery system · Pseudomonas aeruginosa · Staphylococcus aureus · Antibiotic Resistance in Bacteria · Bacterial Infections and Vaccines · Chemistry · Medicine · Yersinia bacterium, plague, ectoparasites research · Microbiology · Pharmacology

• Risques alimentaires, politique des savoirs et processus de recadrage

  Open Access•Elise Demeulenaere, Mathilde Lagrola•Anthropology of food•2026

  Add to list